Immunoclin 10-Q 24 Jul 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Apr. 30, 2014	Jul. 23, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'Immunoclin Corp	'
Entity Central Index Key	'0001520047	'
Document Type	'10-Q	'
Document Period End Date	30-Apr-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--01-31	'
Is Entity's Reporting Status Current?	'Yes	'
Well Known Seasoned Issuer	'No	'
Voluntary Filers	'No	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	26,481,154
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Apr. 30, 2014	Jan. 31, 2014
ASSETS	'	'
Cash	$90,035	$51,956
Accounts receivable	22,658	14,309
Other receivable	7,745	7,745
Prepaid expenses	15,000	'
Current Assets	135,438	74,010
Property and equipment, net (Note 7)	10,048	6,241
Intangibles, net (Note 8)	19,408,851	19,793,466
Goodwill	654,992	654,992
Total Assets	20,209,329	20,528,709
Current Liabilities	'	'
Accounts payable	174,607	177,817
Accrued expenses, primarily management fees	721,811	469,888
Due to related parties (Note 4)	22,822	2,704
Notes payable, related parties (Note 5)	162,062	2,062
Notes payable, stockholders (Note 5)	72,997	72,997
Total Current Liabilities	1,154,299	725,468
STOCKHOLDERS' EQUITY	'	'
Preferred Stock, $0.001 par value, 9,000,000 shares authorized, 0 shares issued and outstanding at April 30, 2014 and January 31, 2014. Series A Preferred stock, $0.001 par value, 1,000,000 shares authorized, 1,000,000 shares issued and outstanding at April 30, 2014 and January 31, 2014	1,000	1,000
Common Stock , $0.001 par value, 290,000,000 shares authorized, 26,421,154 issued and outstanding April 30, 2014 and 26,503,515 at January 31, 2014	26,421	26,504
Prepaid consulting	-495,119	-510,329
Additional paid-in capital	33,206,856	33,164,274
Accumulated deficit	-13,656,328	-12,862,769
Cumulative translation adjustments	-27,800	-15,439
Total Stockholders' Equity	19,055,030	19,803,241
Total Liabilities and Stockholders' Equity	20,209,329	20,528,709
Series A Preferred Stock	'	'
STOCKHOLDERS' EQUITY	'	'
Preferred Stock, $0.001 par value, 9,000,000 shares authorized, 0 shares issued and outstanding at April 30, 2014 and January 31, 2014. Series A Preferred stock, $0.001 par value, 1,000,000 shares authorized, 1,000,000 shares issued and outstanding at April 30, 2014 and January 31, 2014	$1,000	$1,000

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Apr. 30, 2014	Jan. 31, 2014
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	9,000,000	9,000,000
Preferred stock, issued	1,000,000	1,000,000
Preferred stock, outstanding	1,000,000	1,000,000
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	290,000,000	290,000,000
Common stock, shares issued	26,421,154	26,503,515
Common stock, shares outstanding	26,421,154	26,503,515
Series A Preferred Stock	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, issued	1,000,000	1,000,000
Preferred stock, outstanding	1,000,000	1,000,000

Consolidated_Statements_Of_Ope

Consolidated Statements Of Operations And Comprehensive Income (USD $)	3 Months Ended
	Apr. 30, 2014	Apr. 30, 2013
Income Statement [Abstract]	'	'
Revenues	'	'
Operating Expenses	'	'
Amortization	384,615	'
Depreciation	650	364
Management and consulting fees	313,042	'
General and administrative	80,544	35,875
Professional fees	9,055	3,210
Research and development	7,959	5,101
Total operating expenses	795,865	44,550
Net Operating Loss	-795,865	-44,550
Other income (expenses)	'	'
Interest expense, net	'	5
Tax credits, research and development	-2,306	-678
Total other income (expenses)	2,306	673
Net Loss	-793,559	-43,877
Foreign exchange translation adjustment	-12,362	4,124
Comprehensive Income (Loss)	-12,362	4,124
Net Comprehensive Loss	($805,921)	($39,753)
Net loss per Share - basic and diluted	($0.03)	($0.01)
Weighted average shares outstanding - basic and diluted	26,412,053	8,282,363

Consolidated_Statements_Of_Cas

Consolidated Statements Of Cash Flows (USD $)	3 Months Ended
	Apr. 30, 2014	Apr. 30, 2013
Operating Activities	'	'
Net loss for the period	($793,559)	($43,877)
Adjustments to reconcile net loss to cash used in operating activities:	'	'
Amortization	384,615	'
Depreciation	650	364
Amortization of prepaid consulting	57,710	'
Foreign exchange translation	-12,362	4,124
Changes in operating assets and liabilities:	'	'
Accounts receivable	8,349	-20,285
Accounts payable	16,790	-2,322
Accrued expenses, primarily management fees	251,923	-6,177
Net Cash Provided by (Used In) Operating Activities	-102,582	-27,603
Investing Activities	'	'
Purchase of property and equipment	4,457	'
Net Cash Used in Investing Activities	-4,457	'
Financing Activities	'	'
Proceeds from related party loans	20,118	'
Proceeds from notes payable, related party	125,000	21,034
Net Cash Provided by Financing Activities	145,118	21,034
Change in Cash	38,079	-6,569
Cash - Beginning of Period	51,956	167,146
Cash - End of Period	90,035	160,577
Supplemental Disclosures	'	'
Notes payable from legal trust deposit by third party	20,000	'
Notes payable from prepaid expenses paid by related party	15,000	'
Cancellation of common stock	93	'
Common stock issued for prepaid services	42,500	700,000
Interest paid	'	'
Income tax paid	'	'

Consolidated_Statements_Of_Sto

Consolidated Statements Of Stockholders’ Equity (Deficit) (USD $)	Preferred Stock	Common Stock	Additional Paid-In Capital	Prepaid Consulting	Cumulative Translation Adjustments	Deficit	Total
Balance value at Jan. 31, 2013	'	$5,361	$72,094	'	$1,785	($389,628)	($310,388)
Balance shares at Jan. 31, 2013	'	5,361,015	'	'	'	'	'
Preferred stock issued for services, shares	1,000,000	'	'	'	'	'	'
Preferred stock issued for services, value	1,000	'	179,000	'	'	'	180,000
Common stock issued for acquisition, shares	'	10,000,000	'	'	'	'	'
Common stock issued for acquisition, value	'	10,000	19,990,000	'	'	'	20,000,000
Common stock issued for prepaid services, shares	'	10,000,000	'	'	'	'	'
Common stock issued for prepaid services, value	'	10,000	690,000	-700,000	'	'	'
Common stock issued for services, shares	'	6,000,000	'	'	'	'	'
Common stock issued for services, value	'	6,000	11,994,000	'	'	'	12,000,000
Common stock issued to acquire patent, shares	'	100,000	'	'	'	'	'
Common stock issued to acquire patent, value	'	100	199,900	'	'	'	200,000
Common stock issued to settle liability, shares	'	42,500	'	'	'	'	'
Common stock issued to settle liability, value	'	43	86,464	'	'	'	86,507
Cancellation of common stock , shares	'	-5,000,000	'	'	'	'	'
Cancellation of common stock , value	'	-5,000	5,000	'	'	'	'
Amortization of prepaid consulting	'	'	'	189,671	'	'	'
Adjustments to reconcile additional paid-in capital and retained earnings from IML acquisition	'	'	-52,184	'	'	507,176	454,992
Foreign exchange translation adjustment	'	'	'	'	-17,224	'	-17,224
Net loss for the year	'	'	'	'	'	-12,980,317	-12,980,317
Balance value at Jan. 31, 2014	1,000	26,504	33,164,274	-510,329	-15,439	-12,862,769	19,803,241
Balance shares at Jan. 31, 2014	1,000,000	26,503,515	'	'	'	'	'
Common stock issued for prepaid services, value	'	'	'	'	'	'	42,500
Common stock issued for services, shares	'	10,000	'	'	'	'	'
Common stock issued for services, value	'	10	42,490	-42,500	'	'	'
Cancellation of common stock , shares	'	-92,361	'	'	'	'	'
Cancellation of common stock , value	'	-93	92	'	1	'	93
Amortization of prepaid consulting	'	'	'	57,710	'	'	57,710
Foreign exchange translation adjustment	'	'	'	'	-12,362	'	-12,362
Net loss for the year	'	'	'	'	'	-793,559	-793,559
Balance value at Apr. 30, 2014	$1,000	$26,421	$33,206,856	($495,119)	($27,800)	($13,656,328)	$19,055,030
Balance shares at Apr. 30, 2014	1,000,000	26,421,154	'	'	'	'	'

Nature_Of_Operations_And_Conti

Nature Of Operations And Continuance Of Business	3 Months Ended
	Apr. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Nature Of Operations And Continuance Of Business	'
	1. Nature of Operations and Continuance of Business
	Immunoclin Corporation (the “Company”), formerly Pharma Investing News, Inc., was incorporated in the State of Nevada on February 8, 2011.
	On December 13, 2013, the Company acquired through a share for share takeover transaction Immunoclin Limited (“IML”), an England and Wales corporation, which is now a wholly-owned subsidiary. The Company changed both its name to Immunoclin Corporation and its stock symbol to IMCL in conjunction with this acquisition. The Company works on advanced immunology research and development skill to serve the pharmaceutical, biotechnology and food industries, providing comprehensive, clinical and basic science research expertise at a commercial scale and quality.
	Going Concern
	These consolidated financial statements have been prepared on a going concern basis, which assumes that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of April 30, 2014, the Company has minimal revenues, and has a working capital deficit of $1,018,656 and an accumulated deficit of $13,656,328. The continuation of the Company as a going concern is dependent upon the continued financial support from its management, and its ability to identify future investment opportunities and obtain the necessary debt or equity financing, and generating profitable operations from the Company’s future operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Summary_Of_Significant_Account

Summary Of Significant Accounting Policies	3 Months Ended
	Apr. 30, 2014
Accounting Policies [Abstract]	'
Summary Of Significant Accounting Policies	'
	2	Summary of Significant Accounting Policies
		A.	Basis of Presentation
	The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) and are expressed in U.S. dollars.
	Interim Financial Reporting
	While the information presented in the accompanying interim financial statements is unaudited, it includes all adjustments, which are, in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in accordance with generally accepted accounting principles in the United States of America ("GAAP"). These interim financial statements follow the same accounting policies and methods of application as used in the January 31, 2014 audited financial statements of Immunoclin Corporation (the “Company”). All adjustments are of a normal, recurring nature. Interim financial statements and the notes thereto do not contain all of the disclosures normally found in year-end audited financial statements and these Notes to Financial Statements are abbreviated and contain only certain disclosures related to the three month periods ended April 30, 2014 and 2013. It is suggested that these interim financial statements be read in conjunction with the Company’s audited financial statements and related notes for the year ended January 31, 2014 included in our Form 10-K/A, filed with the Securities Exchange Commission on July 7, 2014. Operating results for the three months ended April 30, 2014 are not necessarily indicative of the results that can be expected for the year ending January 31, 2015.
	The operating results of Immunoclin Limited (“IML”), acquired on December 13, 2013, were consolidated with the financial statements of the Company for the three months ended April 30, 2014.
	The Company changed the presentation of prepaid stock-based compensation from prepaid expense (current asset) to prepaid consulting (equity).
	B. Use of Estimates
	The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the consolidated financial statements in the period they are determined.
	C. Basic and Diluted Net Income (Loss) Per Share
	Under ASC 260, "Earnings Per Share" ("EPS"), the Company provides for the calculation of basic and diluted earnings per share. Basic EPS includes no dilution and is computed by dividing income or loss available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution of securities that could share in the earnings or losses of the entity. For the three months ended April 30, 2014 and 2013, basic and diluted loss per share are the same since the calculation of diluted per share amounts would result in an anti-dilutive calculation.
	D. Cash and Cash Equivalents
	The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.
	E. Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable consists principally of trade receivables, which are recorded at the invoiced amount, net of allowances for doubtful accounts and prompt payment discounts. Trade receivables do not bear interest. The allowance for doubtful accounts represents management’s estimate of the amount of probable credit losses in existing accounts receivable, as determined from a review of past due balances and other specific account data. Account balances are written off against the allowance when management determines the receivable is uncollectible. The Company does not have off-balance sheet credit exposure related to its customers.
	F. Prepaid Expense
	Prepaid expenses consist of prepaid audit and travel expenses.
	G. Long-Lived Assets
	Under ASC Topic 360, “Property, Plant, and Equipment”, the Company is required to periodically evaluate the carrying value of long-lived assets to be held and used. ASC Topic 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal.
	The Company is adopting ASU update number 2012-02—Intangibles—Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment whereby the Company will first assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that an indefinite-lived intangible asset is impaired. If, after assessing the totality of events and circumstances, we conclude that it is not more than likely than not that the indefinite-lived intangible asset is impaired, then we are not required to take further action. If the Company concludes otherwise, then we will determine the fair value of the indefinite-lived intangible asset and perform the required quantitative impairment test by comparing the fair value with the carrying amount.
	H. Fair Value Measurements
	Under ASC Topic 820, the Company discloses the estimated fair values of financial instruments. The carrying amounts reported in the balance sheet for current assets and current liabilities qualifying as financial instruments are a reasonable estimate of fair value.
	In accordance with the reporting requirements of ASC Topic 825, Financial Instruments, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the consolidated financial statements when the fair value is different than the carrying value of those financial instruments (see Note 3). The estimated fair value of other current assets and current liabilities approximate their carrying amounts due to the relatively short maturity of these instruments. None of these instruments are held for trading purposes.
	I. Goodwill and Intangible Assets
	Under ASC Topic 350 “Intangibles-Goodwill and Other”, goodwill is not amortized to expense, but rather is assessed or tested for impairment at least annually. Impairment write-downs are charged to results of operations in the period in which the impairment is determined. If certain events occur which might indicate goodwill has been impaired, the goodwill is tested for impairment when such events occur. Other acquired intangible assets with finite lives, such as acquired R&D and patents, are required to be amortized over the estimated lives. These intangibles are generally amortized using the straight-line method over estimated useful lives.
	The Company tests the carrying value of goodwill and indefinite life intangible assets for impairment at least once a year and more frequently if an event or circumstance indicates the asset may be impaired. An impairment loss is recognized if the amount of the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less selling expenses or its value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows (cash generating units).
	The Company did not record an impairment loss on goodwill for the three months ended April 30, 2014 and 2013.
	J. Revenue Recognition
	Revenues are recognized at the time clinical and laboratory services are completed and delivered pursuant to percentage of completion and/or milestone payments as per contracts with the Company’s customers.
	K. Research and Development Expenses
	Under ASC Topic 730 “Research and Development”, costs are expensed as incurred. These expenses include the costs of our proprietary R&D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a product receives regulatory approval, we record upfront and milestone payments made by us to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a product receives regulatory approval, any milestone payments will be recorded as Identifiable intangible assets, less accumulated amortization and, unless the asset is determined to have an indefinite life, amortization of the payments will be on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.
	L. Income Taxes
	Under ASC Topic 740, “Income Taxes”, the Company in required to account for its income taxes through the establishment of a deferred tax asset or liability for the recognition of future deductible or taxable amounts and operating loss and tax credit carry forwards. Deferred tax expense or benefit is recognized as a result of timing differences between the recognition of assets and liabilities for book and tax purposes during the year.
	Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
	Deferred tax assets are recognized for deductible temporary differences and operating loss, and tax credit carry forwards. A valuation allowance is established to reduce that deferred tax asset if it is "more likely than not" that the related tax benefits will not be realized.
	Unfiled Federal Tax Returns: For the years ending January 31, 2014 and 2013, the Company has not filed federal tax returns and may be subject to penalties. The Company estimates that the amount of penalties, if any, will not have a material effect on the results of operations, cash flows or financial position. No provisions have been made in the financial statements for such penalties, if any.
	The Company is planning to have its accountants prepare and file overdue federal tax returns for the years ended January 31, 2014 and 2013 by Q4 of fiscal 2015.
	M. Stock-Based Compensation
	Under ASC Topic 718, ‘‘Compensation-Stock Compensation’’, the Company is required to measure all employee share-based payments, including grants of employee stock options, using a fair-value-based method and the recording of such expense in the statements of operations. The Company has adopted ASC Topic 718 (SFAS 123R) and recognizes stock-based compensation expense using the modified prospective method. As of April 30, 2014 and 2013, the Company has no employee stock options.
	N. Comprehensive Loss
	ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. As of April 30, 2014 and 2013, the Company had foreign exchange translation adjustments of $4,126 and ($12,266), respectively, which are included in other comprehensive income in the consolidated financial statements.
	O. Recent Accounting Pronouncements
	During the three months ended April 30, 2014 and through July 23, 2014, there were several new accounting pronouncements issued by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements.
	P. Reclassifications
	For comparative purposes, certain prior period consolidated financial statements have been reclassified to conform with report classifications of the current year.

Fair_Value_Measurements_And_Di

Fair Value Measurements And Disclosures	3 Months Ended
	Apr. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements and Disclosures	'
	3. Fair Value Measurements and Disclosures
	ASC Topic 820, Fair Value Measurement, establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC Topic 820 are described as follows:
		Level 1
	Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities that the Company can access at the measurement date.
		Level 2
	Inputs to the valuation methodology are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.
		Level 3
	Inputs to the valuation methodology are unobservable inputs for the asset of liability.
	The asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.
	Following is a description of the valuation methodologies used for the Company’s liabilities measured at fair value. There have been no changes in the methodologies used at April 30, 2014.
	Intangibles from IML acquisition: The Company acquired $19,800,000 in R&D intangibles in the acquisition of IML that are valued at fair market value as determined by an independent valuator.
	The preceding methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date. The following tables set forth by level, within the fair value hierarchy, the Company’s assets at fair value as of April 30, 2014.
		Level 1		Level 2		Level 3		Total
	Intangibles from acquisition of IML, net of accumulated amortization		—		—	$	19,408,742	$	19,408,742

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Apr. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	4. Related Party Transactions
	Appointment of director and officer
	On March 1, 2014, Dr. Khadija Benlhassan was appointed director and Chief Scientific Officer pursuant to her management agreement dated January 23, 2014.
	Loans
	On February 7, 2014, Intrinsic Venture Corp. loaned the Company $10,000 via a third-party payment to the Company’s attorney Dean Law Corp. in trust.
	On February 18, 2014, Intrinsic Capital Corp. loaned Immunoclin Limited, the Company’s wholly owned subsidiary, $100,000.
	On March 10, 2014, Intrinsic Capital Corp. loaned the Company $15,000 via a third-party payment to the Company’s auditors Sadler, Gibb & Associates, LLC.
	On April 7, 2014, Intrinsic Capital Corp. loaned the Company $25,000.
	On April 30, 2014, Intrinsic Venture Corp. loan the Company $10,000 via a third-party payment to the Company’s attorney Dean Law Corp. in trust.
	Intrinsic Venture Corp. and Intrinsic Capital Corp. are owned and controlled by the Company’s CFO, J. Scott Munro.
	During the three months ended April 30, 2014, the Company recorded the following related party management fees and stock-based compensation (“SBC”):
	Related Party	Position	Fees		SBC
	Dr. Dorothy Bray	CEO/President	$	57,666	$	—
	J. Scott Munro	CFO		56,666		—
	Chad S. Johnson, Esq.	COO and General Counsel		41,000		—
	Khadija Benlhassan	CSO		36,334		—
	Raymond Dabney	Managing Consultant		57,666		56,895
			$	249,332	$	249,332
	The above table includes management fees and stock-based compensation paid to/earned by companies beneficially owned by the related parties.

Notes_Payable

Notes Payable	3 Months Ended
	Apr. 30, 2014
Debt Disclosure [Abstract]	'
Notes Payable	'
	5. Notes Payable
	The Company has $72,997 (2014; $72,997) in non-interest bearing, unsecured, promissory notes due upon demand in 12 months to Jagpal Holdings Ltd. A note for $55,145 was due and payable on April 25, 2014 and a note for $17,852 is due and payable on June 1, 2014. The Company is currently negotiating with the note holder to extend the notes.
	The Company has $140,000 (2014: $0) in non-interest bearing, unsecured, promissory notes due on June 20, 2015 to Intrinsic Capital Corp. and $22,062 (2014: $2,062) in non-interest bearing, unsecured, promissory notes with $2,062 due on October 21, 2014 and $20,000 due on April 30, 2015 to Intrinsic Venture Corp. Both companies are owned and controlled by the Company’s CFO J. Scott Munro. (see Note 4)

Equity

Equity	3 Months Ended
	Apr. 30, 2014
Equity [Abstract]	'
Equity	'
	6. Equity
	The Company is authorized to issue 290,000,000 shares of common stock with a par value of $0.001 per share. These shares have full voting rights. There were 26,421,154 and 26,503,515 shares of common stock issued and outstanding as of April 30, 2014 and January 31, 2014, respectively.
	The Company is also authorized to issue 1,000,000 shares of Series A preferred stock, with a par value of $0.001 per share. The shares of Series A preferred stock have 51% of the total vote on all shareholder matters and 66-2/3% of the Series A preferred stockholders may make any affirmative vote to amend, alter or repeal and provision of the Articles of Incorporation or the Bylaws of the Company. There were 1,000,000 shares of Series A preferred stock issued and outstanding as of April 30, 2014 and January 31, 2014.
	The Company is also authorized to issue 9,000,000 shares of preferred stock. These shares have full voting rights. There were 0 and 0 issued and outstanding as of April 30, 2014 and January 31, 2014, respectively.
	On March 20, 2014, Prestige Performance Corp. cancelled 92,361 shares of common stock. The Company recorded $92 as additional paid-in capital, $1 to translation adjustments, and ($93) to common stock for the cancellation.
	During the three months ended April 30, 2014, the Company issued the following common stock:
	On April 23, 2014, the Company signed a two-year management consulting agreement with Dr. Marco Kaiser to act as an advisor for molecular biology, genetics, infectious diseases, and DACTELLIGENCE™. Dr. Kaiser was issued 10,000 rule 144 restricted shares of common stock with a fair market value of $42,500, or $4.25 per share, in addition to performance bonuses for services rendered under the agreement.
	Stock Options and Warrants:
	The Company has no stock options or warrants outstanding.

Equipment

Equipment	3 Months Ended
	Apr. 30, 2014
Property, Plant and Equipment [Abstract]	'
Equipment	'
	7. Equipment
			Cost		Accumulated Depreciation		Net Book Value		Net Book Value January 31, 2014
							30-Apr-14
		Computers	$	15,927	$	5,879	$	10,048	$	6,241
	All equipment is stated at cost.  Maintenance and repairs are charged to expense as incurred and the cost of renewals and betterments are capitalized.  Depreciation is computed using the straight-line method over the 5 year estimated lives of the related computer equipment.

Intangible_Assets

Intangible Assets	3 Months Ended
	Apr. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets	'
	8. Intangible Assets
		30-Apr-14		31-Jan-14
	Patents	$	200,000		200,000
	Research and development		19,800,000		19,800,000
	Less accumulated amortization		-591,258		(206,534 )
		$	19,408,742		19,793,466
	Intangible assets are stated at fair value on the date of purchase less accumulated amortization. Amortization is computed using the straight-line method over the estimated lives of the related assets (13 years for intellectual assets).
	On December 13, 2013, the Company acquired the remaining 50% interest in the DACTELLIGENCE™ patent from one of the inventors for consideration of 100,000 shares of common stock with a fair market value of $200,000 or $2.00 per share.
	On December 13, 2013, the Company acquired R&D intangibles in the IML acquisition. An independent valuation firm validated the purchase price for IML to be $20,000,000 consisting of $19,800,000 in intangibles-R&D, 654,992 in goodwill, and ($454,992) in net tangible assets acquired, which was confirmed by a third-party valuator assessment.
	The Company will recognize approximately $1,538,462 in intangible amortization expense per year over the next 13 years with intangibles being fully amortized by fiscal 2028.

Commitments_And_Contingencies

Commitments And Contingencies	3 Months Ended
	Apr. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	9. Commitments and Contingencies
	The Company has a 1,668 sq. ft. laboratory facility located in Paris, France at the Centre de Recherche des Cordeliers (CRC). The laboratory has operated under a lease with University of Pierre and Marie Currie (UPMC) in Immunoclin Limited since 2001. Lease commitments are approximately $38 per square foot or $63,000 per year, plus charges of approximately $4,000. The lease is paid semi-annually on January 1st and June 1st. The Company is currently under negotiations with UPMC to extend the lease, which is set to expire on December 31, 2015.
	The Company’s corporate headquarters is currently on a month-to-month lease of $250 with no other commitments. (See Note 10)
	The Company has no other commitments or contingencies.

Subsequent_Events

Subsequent Events	3 Months Ended
	Apr. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	10. Subsequent Events
	The following loans were made to the Company subsequent to the three months ended April 30, 2014:
	Intrinsic Venture Corp.
		16-May-14		$	14,500
	Intrinsic Capital Corp.
		3-Jun-14		$	100,000
		5-Jun-14			7,500
		30-Jun-14			46,248
				$	153,748
	Intrinsic Venture Corp. and Intrinsic Capital Corp. are owned and controlled by the Company’s CFO, J. Scott Munro.
	On June 30, 2014, $240,000 of the loans made to the Company by Intrinsic Capital Corp. were secured by a non-interest bearing promissory note due upon demand in 12 months. (see Note 4)
	On July 2, 2014, the Company dismissed Sadler, Gibb & Associates, LLC. as its certifying accountant. On July 3, 2014, the Company engaged Turner, Stone & Company, LLP as its new certifying accountant. These changes were announced on Form 8-K filed with the SEC on July 7, 2014 file no 000-54738.
	Agreements and Equity
	On June 18, 201 4, a meeting of the Board of Directors with the unanimous consent approved the issuance of 2,000,000 stock options to each management staff of the Company. Each unregistered stock option is exercisable at a price of $1.45 per share and converted into one common share with expiry five-years from vesting. On June 30, 2014, the Board of Directors signed the resolution to ratify the issuance of the previously approved unregistered stock options. Dr. Dorothy Bray, Chad Johnson, Dr. Khadija Benlhassan, J. Scott Munro, and Raymond Dabney each received 2,000,000 stock options at an exercise price of $1.45 (current market) that expire five-years from vesting. 1,000,000 options vest on each of November 1, 2014 and November 1, 2015.
	Subsequent to the three months ended April 30, 2014, the Company entered into the following agreements with scientific advisors:
	On May 1, 2014, the Company signed a two-year management consulting agreement with Railton Frith and his affiliates to act as advisors for DACTELLIGENCE™. Mr. Frith was issued 10,000 Rule 144 restricted shares of common stock with a fair market value of $37,500, or $3.75 per share, in addition to performance bonuses for services rendered under the agreement.
	On May 7, 2014, the Company signed a two-year management consulting agreement with Professor Antony Bayer and his affiliates to act as advisors for neurology and aging. Prof. Bayer was issued 10,000 Rule 144 restricted shares of common stock with a fair market value of $37,500, or $3.75 per share, in addition to performance bonuses for services rendered under the agreement.
	On May 27, 2014, the Company signed a two-year management consulting agreement with Professor Jean Mariani to act as an advisor for treatments targeting central nervous system diseases and aging. Prof. Mariani was issued 10,000 Rule 144 restricted shares of common stock with a fair market value of $50,000, or $5.00 per share, in addition to performance bonuses for services rendered under the agreement.
	On June 1, 2014, the Company signed a two-year management consulting agreement with Dr. Heinz Ellerbrok and his affiliates to act as advisors for infectious diseases and DACTELLIGENCE™. Dr. Ellerbrok was issued 10,000 Rule 144 restricted shares of common stock with a fair market value of $56,000, or $5.60 per share, in addition to performance bonuses for services rendered under the agreement.
	On June 4, 2014, the Company signed a two-year management consulting agreement with Professor Iwona Wybrańska and her affiliates to act as advisors for nutrigenomics, metabolomics and functional food. Prof. Wybrańska was issued 10,000 Rule 144 restricted shares of common stock with a fair market value of $56,000, or $5.60 per share, in addition to performance bonuses for services rendered under the agreement.
	On June 21, 2014, the Company signed a two-year management consulting agreement with Dr. Gundula Piechotta and her affiliates to act as advisors for infectious diseases and DACTELLIGENCE™. Dr. Piechotta was issued 10,000 Rule 144 restricted shares of common stock with a fair market value of $56,000, or $5.60 per share, in addition to performance bonuses for services rendered under the agreement.
	The Company entered into a 2-year lease, with a 2-year renewal option, for a new corporate office in Washington, DC that will commence on August 1, 2014. Commitments under the lease are $2,900 per month, plus shared costs.
	Common shares reconciliation table:
	Issued and outstanding as of April 30, 2014		26,421,154
	Subsequent event issuances		60,000
	Issued  and outstanding as of July 23, 2014		26,481,154

Summary_Of_Significant_Account1

Summary Of Significant Accounting Policies (Policies)	3 Months Ended
	Apr. 30, 2014
Accounting Policies [Abstract]	'
Basis Of Presentation	'
	A.	Basis of Presentation
	The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) and are expressed in U.S. dollars.
Interim Financial Reporting	'
	Interim Financial Reporting
	While the information presented in the accompanying interim financial statements is unaudited, it includes all adjustments, which are, in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in accordance with generally accepted accounting principles in the United States of America ("GAAP"). These interim financial statements follow the same accounting policies and methods of application as used in the January 31, 2014 audited financial statements of Immunoclin Corporation (the “Company”). All adjustments are of a normal, recurring nature. Interim financial statements and the notes thereto do not contain all of the disclosures normally found in year-end audited financial statements and these Notes to Financial Statements are abbreviated and contain only certain disclosures related to the three month periods ended April 30, 2014 and 2013. It is suggested that these interim financial statements be read in conjunction with the Company’s audited financial statements and related notes for the year ended January 31, 2014 included in our Form 10-K/A, filed with the Securities Exchange Commission on July 7, 2014. Operating results for the three months ended April 30, 2014 are not necessarily indicative of the results that can be expected for the year ending January 31, 2015.
	The operating results of Immunoclin Limited (“IML”), acquired on December 13, 2013, were consolidated with the financial statements of the Company for the three months ended April 30, 2014.
	The Company changed the presentation of prepaid stock-based compensation from prepaid expense (current asset) to prepaid consulting (equity).
Use Of Estimates	'
	B. Use of Estimates
	The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the consolidated financial statements in the period they are determined.
Basic And Diluted Net Income (loss) Per Share	'
	C. Basic and Diluted Net Income (Loss) Per Share
	Under ASC 260, "Earnings Per Share" ("EPS"), the Company provides for the calculation of basic and diluted earnings per share. Basic EPS includes no dilution and is computed by dividing income or loss available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution of securities that could share in the earnings or losses of the entity. For the three months ended April 30, 2014 and 2013, basic and diluted loss per share are the same since the calculation of diluted per share amounts would result in an anti-dilutive calculation.
Cash And Cash Equivalents	'
	D. Cash and Cash Equivalents
	The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.
Accounts Receivable And Allowance For Doubtful Accounts	'
	E. Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable consists principally of trade receivables, which are recorded at the invoiced amount, net of allowances for doubtful accounts and prompt payment discounts. Trade receivables do not bear interest. The allowance for doubtful accounts represents management’s estimate of the amount of probable credit losses in existing accounts receivable, as determined from a review of past due balances and other specific account data. Account balances are written off against the allowance when management determines the receivable is uncollectible. The Company does not have off-balance sheet credit exposure related to its customers.
Prepaid Expense	'
	F. Prepaid Expense
	Prepaid expenses consist of prepaid audit and travel expenses.
Long-lived Assets	'
	G. Long-Lived Assets
	Under ASC Topic 360, “Property, Plant, and Equipment”, the Company is required to periodically evaluate the carrying value of long-lived assets to be held and used. ASC Topic 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal.
	The Company is adopting ASU update number 2012-02—Intangibles—Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment whereby the Company will first assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that an indefinite-lived intangible asset is impaired. If, after assessing the totality of events and circumstances, we conclude that it is not more than likely than not that the indefinite-lived intangible asset is impaired, then we are not required to take further action. If the Company concludes otherwise, then we will determine the fair value of the indefinite-lived intangible asset and perform the required quantitative impairment test by comparing the fair value with the carrying amount.
Fair Value Measurements	'
	H. Fair Value Measurements
	Under ASC Topic 820, the Company discloses the estimated fair values of financial instruments. The carrying amounts reported in the balance sheet for current assets and current liabilities qualifying as financial instruments are a reasonable estimate of fair value.
	In accordance with the reporting requirements of ASC Topic 825, Financial Instruments, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the consolidated financial statements when the fair value is different than the carrying value of those financial instruments (see Note 3). The estimated fair value of other current assets and current liabilities approximate their carrying amounts due to the relatively short maturity of these instruments. None of these instruments are held for trading purposes.
Goodwill And Intangible Assets	'
	I. Goodwill and Intangible Assets
	Under ASC Topic 350 “Intangibles-Goodwill and Other”, goodwill is not amortized to expense, but rather is assessed or tested for impairment at least annually. Impairment write-downs are charged to results of operations in the period in which the impairment is determined. If certain events occur which might indicate goodwill has been impaired, the goodwill is tested for impairment when such events occur. Other acquired intangible assets with finite lives, such as acquired R&D and patents, are required to be amortized over the estimated lives. These intangibles are generally amortized using the straight-line method over estimated useful lives.
	The Company tests the carrying value of goodwill and indefinite life intangible assets for impairment at least once a year and more frequently if an event or circumstance indicates the asset may be impaired. An impairment loss is recognized if the amount of the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less selling expenses or its value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows (cash generating units).
	The Company did not record an impairment loss on goodwill for the three months ended April 30, 2014 and 2013.
Revenue Recognition	'
	J. Revenue Recognition
	Revenues are recognized at the time clinical and laboratory services are completed and delivered pursuant to percentage of completion and/or milestone payments as per contracts with the Company’s customers.
Research And Development Expenses	'
	K. Research and Development Expenses
	Under ASC Topic 730 “Research and Development”, costs are expensed as incurred. These expenses include the costs of our proprietary R&D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a product receives regulatory approval, we record upfront and milestone payments made by us to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a product receives regulatory approval, any milestone payments will be recorded as Identifiable intangible assets, less accumulated amortization and, unless the asset is determined to have an indefinite life, amortization of the payments will be on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.
Income Taxes	'
	L. Income Taxes
	Under ASC Topic 740, “Income Taxes”, the Company in required to account for its income taxes through the establishment of a deferred tax asset or liability for the recognition of future deductible or taxable amounts and operating loss and tax credit carry forwards. Deferred tax expense or benefit is recognized as a result of timing differences between the recognition of assets and liabilities for book and tax purposes during the year.
	Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
	Deferred tax assets are recognized for deductible temporary differences and operating loss, and tax credit carry forwards. A valuation allowance is established to reduce that deferred tax asset if it is "more likely than not" that the related tax benefits will not be realized.
	Unfiled Federal Tax Returns: For the years ending January 31, 2014 and 2013, the Company has not filed federal tax returns and may be subject to penalties. The Company estimates that the amount of penalties, if any, will not have a material effect on the results of operations, cash flows or financial position. No provisions have been made in the financial statements for such penalties, if any.
	The Company is planning to have its accountants prepare and file overdue federal tax returns for the years ended January 31, 2014 and 2013 by Q4 of fiscal 2015.
Stock Based Compensation	'
	M. Stock-Based Compensation
	Under ASC Topic 718, ‘‘Compensation-Stock Compensation’’, the Company is required to measure all employee share-based payments, including grants of employee stock options, using a fair-value-based method and the recording of such expense in the statements of operations. The Company has adopted ASC Topic 718 (SFAS 123R) and recognizes stock-based compensation expense using the modified prospective method. As of April 30, 2014 and 2013, the Company has no employee stock options.
Comprehensive Loss	'
	N. Comprehensive Loss
	ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. As of April 30, 2014 and 2013, the Company had foreign exchange translation adjustments of $4,126 and ($12,266), respectively, which are included in other comprehensive income in the consolidated financial statements.
Recent Accounting Pronouncements	'
	O. Recent Accounting Pronouncements
	During the three months ended April 30, 2014 and through July 23, 2014, there were several new accounting pronouncements issued by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements.
Reclassification	'
	P. Reclassifications
	For comparative purposes, certain prior period consolidated financial statements have been reclassified to conform with report classifications of the current year.

Fair_Value_Measurements_And_Di1

Fair Value Measurements And Disclosures (Tables)	3 Months Ended
	Apr. 30, 2014
Fair Value Disclosures [Abstract]	'
Schedule Of Fair Value Measurement And Disclosure	'
	The following tables set forth by level, within the fair value hierarchy, the Company’s assets at fair value as of April 30, 2014.
		Level 1		Level 2		Level 3		Total
	Intangibles from acquisition of IML, net of accumulated amortization		—		—	$	19,408,742	$	19,408,742

Related_Party_Transactions_Tab

Related Party Transactions (Tables)	3 Months Ended
	Apr. 30, 2014
Related Party Transactions [Abstract]	'
Schedule Of Related Party Transactions	'
	During the three months ended April 30, 2014, the Company recorded the following related party management fees and stock-based compensation (“SBC”):
	Related Party	Position	Fees		SBC
	Dr. Dorothy Bray	CEO/President	$	57,666	$	—
	J. Scott Munro	CFO		56,666		—
	Chad S. Johnson, Esq.	COO and General Counsel		41,000		—
	Khadija Benlhassan	CSO		36,334		—
	Raymond Dabney	Managing Consultant		57,666		56,895
			$	249,332	$	249,332

Equipment_Tables

Equipment (Tables)	3 Months Ended
	Apr. 30, 2014
Property, Plant and Equipment [Abstract]	'
Schedule Of Equipment	'
			Cost		Accumulated Depreciation		Net Book Value		Net Book Value January 31, 2014
							30-Apr-14
		Computers	$	15,927	$	5,879	$	10,048	$	6,241

Intangible_Assets_Tables

Intangible Assets (Tables)	3 Months Ended
	Apr. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule Of Intangible Assets	'
		30-Apr-14		31-Jan-14
	Patents	$	200,000		200,000
	Research and development		19,800,000		19,800,000
	Less accumulated amortization		-591,258		(206,534 )
		$	19,408,742		19,793,466

Subsequent_Events_Tables

Subsequent Events (Tables)	3 Months Ended
	Apr. 30, 2014
Subsequent Events Tables	'
Schedule Of Loans	'
	The following loans were made to the Company subsequent to the three months ended April 30, 2014:
	Intrinsic Venture Corp.
		16-May-14		$	14,500
	Intrinsic Capital Corp.
		3-Jun-14		$	100,000
		5-Jun-14			7,500
		30-Jun-14			46,248
				$	153,748
Schedule Of Common Shares Reconciliation	'
	Common shares reconciliation table:
	Issued and outstanding as of April 30, 2014		26,421,154
	Subsequent event issuances		60,000
	Issued  and outstanding as of July 23, 2014		26,481,154

Recovered_Sheet1

Fair Value Measurements and Disclosures (Details) (USD $)	Apr. 30, 2014	Jan. 31, 2014
Intangibles from acquisition of IML, net of accumulated amortization	$19,408,742	$19,793,466
Level 1	'	'
Intangibles from acquisition of IML, net of accumulated amortization	'	'
Level 2	'	'
Intangibles from acquisition of IML, net of accumulated amortization	'	'
Level 3	'	'
Intangibles from acquisition of IML, net of accumulated amortization	$19,408,742	'

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	3 Months Ended
	Apr. 30, 2014
Management fees	$249,332
Stock based compensation	249,332
Dr. Dorothy Bray - CEO	'
Management fees	57,666
J. Scott Munro - Chief Financial Officer	'
Management fees	56,666
Chad S. Johnson - COO	'
Management fees	41,000
Khadija Benlhassan - Chief Scientific Officer	'
Management fees	36,334
Raymond Dabney - Managing Consultant	'
Management fees	57,666
Stock based compensation	$56,895

Equipment_Details

Equipment (Details) (USD $)	Apr. 30, 2014	Jan. 31, 2014
Net Book Value	$10,048	$6,241
Computer	'	'
Cost	15,927	'
Accumulated Depreciation	5,879	'
Net Book Value	$10,048	$6,241

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	Apr. 30, 2014	Jan. 31, 2014
Finite-Lived Intangible Assets [Line Items]	'	'
Less accumulated amortization	($591,258)	($206,534)
Total	19,408,742	19,793,466
Patents	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite lived intangible assets, gross	200,000	200,000
Research And Development	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite lived intangible assets, gross	$19,800,000	$19,800,000

Subsequent_Events_Schedule_Of_

Subsequent Events (Schedule Of Loans) (Details) (USD $)

Jul. 23, 2014

Apr. 30, 2014

Jan. 31, 2014

Apr. 30, 2014

Jan. 31, 2014

Apr. 30, 2014

Jan. 31, 2014

Apr. 30, 2014

Feb. 07, 2014

Apr. 07, 2014

Mar. 10, 2014

16-May-14

Jun. 03, 2014

Jun. 05, 2014

Jun. 30, 2014

Jun. 30, 2014

Loan Payable - Intrinsic Venture Corp

Loan Payable - Intrinsic Venture Corp

Loan Payable - Intrinsic Capital Corp

Loan Payable - Intrinsic Capital Corp

J. Scott Munro - Chief Financial Officer

J. Scott Munro - Chief Financial Officer

J. Scott Munro - Chief Financial Officer

J. Scott Munro - Chief Financial Officer

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Loan Payable - Intrinsic Venture Corp

Loan Payable - Intrinsic Venture Corp

Loan Payable - Intrinsic Capital Corp

Loan Payable - Intrinsic Capital Corp

J. Scott Munro - Chief Financial Officer

J. Scott Munro - Chief Financial Officer

J. Scott Munro - Chief Financial Officer

J. Scott Munro - Chief Financial Officer

J. Scott Munro - Chief Financial Officer

Loan Payable - Intrinsic Venture Corp

Loan Payable - Intrinsic Capital Corp

Loan Payable - Intrinsic Capital Corp

Loan Payable - Intrinsic Capital Corp

Loans Payable Dated June 30, 2014 - Intrinsic Capital Corp

Loans payable

$153,748

$162,062

$2,062

$22,062

$2,062

$140,000

$0

$10,000

$10,000

$25,000

$15,000

$14,500

$100,000

$7,500

$240,000

$46,248

Debt instrument issuance date

'

'

'

'

'

'

'

'

'

'

'

16-May-14

3-Jun-14

5-Jun-14

'

30-Jun-14

Subsequent_Events_Schedule_Of_1

Subsequent Events (Schedule Of Common Shares Reconciliation) (Details)	Apr. 30, 2014	Jan. 31, 2014	Jul. 23, 2014
			Subsequent Event
Common stock, shares issued	26,421,154	26,503,515	26,481,154
Common stock, shares outstanding	26,421,154	26,503,515	26,481,154
Subsequent event issuances and cancellation	'	'	60,000

Nature_Of_Operations_And_Conti1

Nature Of Operations And Continuance Of Business (Narrative) (Details) (USD $)	Apr. 30, 2014
Nature Of Operations And Continuance Of Business Narrative Details	'
Working capital deficit	$1,018,656

Related_Party_Transactions_Nar

Related Party Transactions (Narrative) (Details) (USD $)

Jul. 23, 2014

Apr. 30, 2014

Jan. 31, 2014

Apr. 30, 2014

Jan. 31, 2014

Apr. 30, 2014

Jan. 31, 2014

Apr. 30, 2014

Feb. 07, 2014

Feb. 18, 2014

Apr. 07, 2014

Mar. 10, 2014

Loan Payable - Intrinsic Venture Corp

Loan Payable - Intrinsic Venture Corp

Loan Payable - Intrinsic Capital Corp

Loan Payable - Intrinsic Capital Corp

J. Scott Munro - Chief Financial Officer

J. Scott Munro - Chief Financial Officer

J. Scott Munro - Chief Financial Officer

J. Scott Munro - Chief Financial Officer

J. Scott Munro - Chief Financial Officer

Loan Payable - Intrinsic Venture Corp

Loan Payable - Intrinsic Venture Corp

Intrinsic Capital Corp. loaned Immunoclin Limited (Subsidiary)

Loan Payable - Intrinsic Capital Corp

Loan Payable - Intrinsic Capital Corp

Loan from related party

$153,748

$162,062

$2,062

$22,062

$2,062

$140,000

$0

$10,000

$10,000

$100,000

$25,000

$15,000

Notes_Payable_Narrative_Detail

Notes Payable (Narrative) (Details) (USD $)	Jul. 23, 2014	Apr. 30, 2014	Jan. 31, 2014	Apr. 30, 2014	Apr. 30, 2014	Apr. 30, 2014	Apr. 30, 2014	Jan. 31, 2014	Apr. 30, 2014	Jan. 31, 2014
				Promissory Note 1 - Jagpal Holdings Ltd	Promissory Note 2 - Jagpal Holdings Ltd	Promissory Note - Jagpal Holdings Ltd	Loan Payable - Intrinsic Capital Corp	Loan Payable - Intrinsic Capital Corp	Loan Payable - Intrinsic Venture Corp	Loan Payable - Intrinsic Venture Corp
Notes payable	'	$72,997	$72,997	$55,145	$17,852	'	'	'	'	'
Note maturity description	'	'	'	'	'	'	'	'	'	'
						Due upon demand in 12 months
									Promissory notes with $2,062 due on October 21, 2014 and $20,000 due on April 30, 2015
Debt instrument description	'	'	'	'	'	'	'It was non-interest bearing, unsecured promissory notes.	'	'It was non-interest bearing, unsecured promissory notes.	'
						It was non-interest bearing, unsecured promissory notes.
Note maturity date	'	'	'	25-Apr-14	1-Jun-14	'	20-Jun-15	'	'	'
Loan from related party	$153,748	$162,062	$2,062	'	'	'	$140,000	$0	$22,062	$2,062

Equity_Narrative_Details

Equity (Narrative) (Details) (USD $)

3 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

Apr. 30, 2014

Apr. 30, 2013

Jan. 31, 2014

Mar. 20, 2014

Apr. 30, 2014

Jan. 31, 2014

Mar. 20, 2014

Apr. 30, 2014

Jan. 31, 2014

Mar. 20, 2014

Apr. 30, 2014

Jan. 31, 2014

Apr. 23, 2014

Apr. 30, 2014

Common Stock

Common Stock

Common Stock

Additional Paid-In Capital

Additional Paid-In Capital

Additional Paid-In Capital

Cumulative Translation Adjustments

Cumulative Translation Adjustments

Cumulative Translation Adjustments

Rule 144 Restricted Stock

Series A Preferred Stock

Consulting Agreement - Dr. Marco Kaiser

Preferred stock voting rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

The shares of Series A preferred stock have 51% of the total vote on all shareholder matters and 66-2/3% of the Series A preferred stockholders may make any affirmative vote to amend, alter or repeal and provision of the Articles of Incorporation or the Bylaws of the Company.

Share price, per share

'

'

'

'

'

'

'

'

'

'

'

'

$4.25

'

Shares issued for service, shares

'

'

'

'

10,000

6,000,000

'

'

'

'

'

'

10,000

'

Shares issued for service, value

'

'

$12,000,000

'

$10

$6,000

'

$42,490

$11,994,000

'

'

'

$42,500

'

Cancellation of common stock by Prestige Performance Corp, Shares

'

'

'

92,361

-92,361

-5,000,000

'

'

'

'

'

'

'

'

Cancellation of common stock by Prestige Performance Corp, Value

$93

'

'

$93

($93)

($5,000)

$92

$92

$5,000

$1

$1

'

'

'

Equipment_Narrative_Details

Equipment (Narrative) (Details) (Computer)	3 Months Ended
	Apr. 30, 2014
Computer	'
Estimated useful life	'5 years

Intangible_Assets_Narrative_De

Intangible Assets (Narrative) (Details) (USD $)	3 Months Ended		12 Months Ended	3 Months Ended	0 Months Ended	12 Months Ended	0 Months Ended
	Apr. 30, 2014	Apr. 30, 2013	Jan. 31, 2014	Apr. 30, 2014	Dec. 13, 2013	Jan. 31, 2014	Dec. 13, 2013
				Intangible Assets	Immunoclin Limited (IML)	Common Stock	Common Stock
							Patents
Share price, per share	'	'	'	'	'	'	$2
Stock issued to acquire patent, shares	'	'	'	'	'	100,000	100,000
Stock issued to acquire patent, value	'	'	$200,000	'	'	$100	$200,000
Purchase price	'	'	'	'	20,000,000	'	'
Intangibles-R&D	'	'	'	'	19,800,000	'	'
Goodwill	654,992	'	654,992	'	654,992	'	'
Net tangible assets	'	'	'	'	-454,992	'	'
Amortization expenses of intangible	$384,615	'	'	$1,538,462	'	'	'
Estimated life of intangible assets	'	'	'	'13 years	'	'	'
Full amortization description	'	'	'	'	'	'	'
				Intangibles being fully amortized by fiscal 2028.

Commitments_And_Contingencies_

Commitments And Contingencies (Narrative) (Details) (Lease Agreements, USD $)	3 Months Ended
	Apr. 30, 2014
Lease Agreements	'
Lease commitment terms	'
	Lease commitments are approximately $38 per square foot or $63,000 per year, plus charges of approximately $4,000. The lease is paid semi-annually on January 1st and June 1st.
Lease expiration date	31-Dec-15
Monthly lease for company corporate headquarters	$250

Subsequent_Events_Narrative_De

Subsequent Events (Narrative) (Details) (USD $)

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

Apr. 30, 2014

Jan. 31, 2014

Jul. 23, 2014

Apr. 30, 2014

Jan. 31, 2014

Jun. 18, 2014

Apr. 30, 2014

Jan. 31, 2014

Apr. 07, 2014

Mar. 10, 2014

Aug. 01, 2014

1-May-14

1-May-14

7-May-14

27-May-14

Jun. 01, 2014

Jun. 04, 2014

Jun. 21, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 05, 2014

Jun. 03, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Common Stock

Common Stock

Common Stock

Loan Payable - Intrinsic Capital Corp

Loan Payable - Intrinsic Capital Corp

J. Scott Munro - Chief Financial Officer

J. Scott Munro - Chief Financial Officer

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Board Of Directors

Loan Payable - Intrinsic Capital Corp

Loan Payable - Intrinsic Capital Corp

Rule 144 Restricted Stock

Rule 144 Restricted Stock

Rule 144 Restricted Stock

Rule 144 Restricted Stock

Rule 144 Restricted Stock

Rule 144 Restricted Stock

Rule 144 Restricted Stock

J. Scott Munro - Chief Financial Officer

J. Scott Munro - Chief Financial Officer

J. Scott Munro - Chief Financial Officer

J. Scott Munro - Chief Financial Officer

Dr. Dorothy Bray - Director And CEO/President

Chad S. Johnson - COO

Khadija Benlhassan - Chief Scientific Officer

Raymond Dabney - Managing Consultant

Consulting Agreement - Railton Frith

Consulting Agreement - Railton Frith

Consulting Agreement - Professor Antony Bayer

Consulting Agreement - Professor Jean Mariani

Consulting Agreement - Dr. Heinz Ellerbrok

Consulting Agreement - Professor Iwona Wybranska

Consulting Agreement - Dr. Gundula Piechotta

Loan Payable - Intrinsic Capital Corp

Loan Payable - Intrinsic Capital Corp

Loan Payable - Intrinsic Capital Corp

Loan from related party

$162,062

$2,062

$153,748

'

'

'

$140,000

$0

$25,000

$15,000

'

'

'

'

'

'

'

'

'

$240,000

$7,500

$100,000

'

'

'

'

Debt maturity description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Due upon demand in 12 months

Debt instrument description

'

'

'

'

'

'

'It was non-interest bearing, unsecured promissory notes.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non-interest bearing promissory note

Shares issued for service, shares

'

'

'

10,000

6,000,000

'

'

'

'

'

'

10,000

'

10,000

10,000

10,000

10,000

10,000

'

'

'

'

'

'

'

'

Shares issued for service, value

'

$12,000,000

'

$10

$6,000

'

'

'

'

'

'

$37,500

'

$37,500

$50,000

$56,000

$56,000

$56,000

'

'

'

'

'

'

'

'

Share price, per share

'

'

'

'

'

'

'

'

'

'

'

'

$3.75

$3.75

$5

$5.60

$5.60

$5.60

'

'

'

'

'

'

'

'

Shares issued for share based compensation

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

2,000,000

2,000,000

2,000,000

2,000,000

Stock options exercise price

'

'

'

'

'

$1.45

'

'

'

'

'

'

'

'

'

'

'

'

$1.45

'

'

'

$1.45

$1.45

$1.45

$1.45

Option vesting period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1,000,000 options vest on each of November 1, 2014 and November 1, 2015

'

'

'

'1,000,000 options vest on each of November 1, 2014 and November 1, 2015

'1,000,000 options vest on each of November 1, 2014 and November 1, 2015

'1,000,000 options vest on each of November 1, 2014 and November 1, 2015

'1,000,000 options vest on each of November 1, 2014 and November 1, 2015

Lease description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

The Company entered into a 2-year lease, with a 2-year renewal option, for a new corporate office in Washington, DC that will commence on August 1, 2014. Commitments under the lease are $2,900 per month, plus shared costs.